BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 16733577)

  • 1. Are branched chain fatty acids the natural substrates for P450(BM3)?
    Cryle MJ; Espinoza RD; Smith SJ; Matovic NJ; De Voss JJ
    Chem Commun (Camb); 2006 Jun; (22):2353-5. PubMed ID: 16733577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
    Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
    Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective hydroxylation of highly branched fatty acids and their derivatives by CYP102A1 from Bacillus megaterium.
    Budde M; Morr M; Schmid RD; Urlacher VB
    Chembiochem; 2006 May; 7(5):789-94. PubMed ID: 16566047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the conserved threonine in P450 BM3 oxygen activation: substrate-determined hydroxylation activity of the Thr268Ala mutant.
    Cryle MJ; De Voss JJ
    Chembiochem; 2008 Jan; 9(2):261-6. PubMed ID: 18161730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation.
    Oliver CF; Modi S; Sutcliffe MJ; Primrose WU; Lian LY; Roberts GC
    Biochemistry; 1997 Feb; 36(7):1567-72. PubMed ID: 9048540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options.
    Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL
    Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dimeric form of flavocytochrome P450 BM3 is catalytically functional as a fatty acid hydroxylase.
    Neeli R; Girvan HM; Lawrence A; Warren MJ; Leys D; Scrutton NS; Munro AW
    FEBS Lett; 2005 Oct; 579(25):5582-8. PubMed ID: 16214136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imidazolyl carboxylic acids as mechanistic probes of flavocytochrome P-450 BM3.
    Noble MA; Quaroni L; Chumanov GD; Turner KL; Chapman SK; Hanzlik RP; Munro AW
    Biochemistry; 1998 Nov; 37(45):15799-807. PubMed ID: 9843385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
    Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
    Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A.
    Schwaneberg U; Schmidt-Dannert C; Schmitt J; Schmid RD
    Anal Biochem; 1999 May; 269(2):359-66. PubMed ID: 10222011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cobaltocene-mediated catalytic monooxygenation using holo and heme domain cytochrome P450 BM3.
    Udit AK; Arnold FH; Gray HB
    J Inorg Biochem; 2004 Sep; 98(9):1547-50. PubMed ID: 15337607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclopropyl fatty acids implicate a radical but not a cation as an intermediate in P450BM3-catalysed hydroxylations.
    Cryle MJ; Stuthe JM; Ortiz de Montellano PR; De Voss JJ
    Chem Commun (Camb); 2004 Mar; (5):512-3. PubMed ID: 14973583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium.
    Urlacher VB; Schmid RD
    Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074
    [No Abstract]   [Full Text] [Related]  

  • 15. Roles of key active-site residues in flavocytochrome P450 BM3.
    Noble MA; Miles CS; Chapman SK; Lysek DA; MacKay AC; Reid GA; Hanzlik RP; Munro AW
    Biochem J; 1999 Apr; 339 ( Pt 2)(Pt 2):371-9. PubMed ID: 10191269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of dioxygen catalyzed by pyrene-wired heme domain cytochrome P450 BM3 electrodes.
    Udit AK; Hill MG; Bittner VG; Arnold FH; Gray HB
    J Am Chem Soc; 2004 Aug; 126(33):10218-9. PubMed ID: 15315414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3.
    Peters MW; Meinhold P; Glieder A; Arnold FH
    J Am Chem Soc; 2003 Nov; 125(44):13442-50. PubMed ID: 14583039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered alkane-hydroxylating cytochrome P450(BM3) exhibiting nativelike catalytic properties.
    Fasan R; Chen MM; Crook NC; Arnold FH
    Angew Chem Int Ed Engl; 2007; 46(44):8414-8. PubMed ID: 17886313
    [No Abstract]   [Full Text] [Related]  

  • 19. P450BM-3: absolute configuration of the primary metabolites of palmitic acid.
    Truan G; Komandla MR; Falck JR; Peterson JA
    Arch Biochem Biophys; 1999 Jun; 366(2):192-8. PubMed ID: 10356283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of a minimal enriched P450 BM3 mutant library for hydroxylation of cyclic and acyclic alkanes.
    Weber E; Seifert A; Antonovici M; Geinitz C; Pleiss J; Urlacher VB
    Chem Commun (Camb); 2011 Jan; 47(3):944-6. PubMed ID: 21079837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.